"Das Marienhospital Osnabrück (MHO) wurde 1859 gegründet. Sein medizinisches Angebot hat sich stetig weiterentwickelt, sodass es heute nahezu das gesamte Spektrum der Maximalversorgung abdeckt. 1800 Mitarbeitende sind im MHO beschäftigt und versorgen jährlich rund 30.000 stationäre und 70.000 ambulante Patient*innen. Gemeinsam mit dem Christlichen Kinderhospital Osnabrück bildet das Marienhospital den größten Krankenhausstandort der Region. Zudem ist es als Lehrkrankenhaus der Medizinischen Hochschule Hannover anerkannt."

During the past decade, Niels-Stensen-Kliniken Marienhospital Osnabrück conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 1 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Niels-Stensen-Kliniken Marienhospital Osnabrück" #1 sponsor was "Abbott Medical Devices" with 5 trials, followed by "Biotronik SE & Co. KG" with 2 trials sponsored, "AGO Research GmbH" with 1 trials sponsored, "AstraZeneca" with 1 trials sponsored and "Biotronik AG" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Niels-Stensen-Kliniken Marienhospital Osnabrück" #1 collaborator was "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 1 trials as a collaborator, "Australia New Zealand Gynaecological Oncology Group" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Niels-Stensen-Kliniken Marienhospital Osnabrück" are "Heart Failure" (4 trials), "Arrhythmias, Cardiac" (1 trials), "Brain and Central Nervous System Tumors" (1 trials), "Cardiac Death" (1 trials) and "Cardiac Resynchronization Therapy" (1 trials). Many other conditions were trialed in "Niels-Stensen-Kliniken Marienhospital Osnabrück" in a lesser frequency.

Most popular intervention types in "Niels-Stensen-Kliniken Marienhospital Osnabrück" are "Device" (11 trials), "Drug" (3 trials), "Biological" (2 trials), "Other" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "radiation therapy" (2 trials), "Bevacizumab" (1 trials), "BioMimics 3D Stent" (1 trials), "Carboplatin" (1 trials) and "Device Implantation" (1 trials). Other intervention names were less common.

The vast majority of trials in "Niels-Stensen-Kliniken Marienhospital Osnabrück" are 16 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Niels-Stensen-Kliniken Marienhospital Osnabrück". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Niels-Stensen-Kliniken Marienhospital Osnabrück, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Niels-Stensen-Kliniken Marienhospital Osnabrück, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".